Hepatitis B e antigen seroconversion: Effects of lamivudine alone or in combination with interferon alpha

Journal of Medical Virology

Volumn 61, Issue 3, 2000, Pages 374-379

  Farrell, Geoffrey ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Chronic hepatitis B; Hepatitis B e antigen seroconversion; Pathogenesis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG;

ARTICLE; DISEASE COURSE; DRUG TOLERABILITY; HEPATITIS B; HUMAN; LONG TERM CARE; NONHUMAN; PATHOGENESIS; SEROCONVERSION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE;

DNA VIRUSES; HEPATITIS B VIRUS;

EID: 0034129935     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-9071(200007)61:3<374::AID-JMV16>3.0.CO;2-7     Document Type: Article

References (43)

1. Alexander GJM, Brahm J, Fagan EA, Smith HM, Daniels HM, Eddleston ALWF, Williams R. 1987. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet 2:66-69.
2. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, Boehme R, Panebianco R, Fiaccadori F, Ferrari C. 1998. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 102:968-975.
3. Brunetto MR, Giarin M, Saracco G, Oliveri F, Calvo P, Capra G, Randone A, Abate ML, Manzini P, Capalbo M, Piantino P, Verme G, Bonino F. 1993. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 105:845-850.
4. Catterall AP, King R, Lau JYN, Daniels HM, Alexander GJM, Murray-Lyon IM, Williams R. 1993. Interferon-α therapy with and without interferon-α priming in patients with chronic hepatitis B infection. J Antimicrob Chemother 31:777-782.
5. Chang TT, Lai CL, Leung NWY, Guan R, Lim SG, Lee CM, Ng KY, Edmundson S, Stevenson C, Dent JC. 1999. Enhanced HBeAg seroconversion rates in Chinese patients on lamivudine. Hepatology 30:421A.
6. Chien R-N, Liaw Y-F, Atkins M for the Asian Lamivudine Trial Group. 1999. Pretherapy alanine transaminase level as a determinant for hepatitis B e Antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 30: 770-774.
7. Chu CM, Karayiannis P, Fowler MJF, Monjardino J, Liaw YF, Thomas HC. 1985. Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology 5:431-434.
8. Chu CM, Liaw Y-F. 1997. Natural history of chronic hepatitis B virus infection: an immunopathological study. J Gastroenterol Hepatol 12(Suppl):S218-S222.
9. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333:1657-1661.
10. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann H-WL, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA for the US Lamivudine Investigator Group. 1999a. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341:1256-1269.
11. Dienstag J, Lai CL, Hann HWL, Leung NWY, Grimm IS, Schiff E, Woessner M, Dent J, Crowther L, Brown NA. 1999b. Natural history and lamivudine response in Asians versus Westerners with chronic hepatitis B. Gastroenterology. Presented at the 39th ICACC conference, San Francisco. (Abstract 2055, page 446).
12. Dusheiko G. 1999. Hepatitis B. In: McIntyre N, Benhamou JP, Bircker J, Rizzetto M, Rodes J, editors. The Oxford textbook of clinical hepatology, second edition. Oxford: Oxford Medical Publications. p 876-896.
13. Fattovich G, Giustina G, Sanchez-Tapías J, Quero C, Mas A, Olívotto PG, Solínas A, Almasio P, Hadziyannis S, Degos F, de Moura MC, Krogsgaard K, Pantalena M, Realdi G, Corrocher R, Schalm SW, and the European Concerted Action on Viral Hepatitis (EUROHEP). 1998. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol 93:896-900.
14. Gaeta GB, Nardiello S, Pizzella T, Russo G, Maisto A, Sardaro C, Galanti B, Giusti G. 1995. Semiquantitative anti-HBc IgM detection in children with chronic hepatitis B: a long-term follow-up study. J Med Virol 46:173-177.
15. Gitlin N. 1997. Hepatitis B: diagnosis, prevention, and treatment. Clin Chem 43:1500-1506.
16. Goodman Z, Dhillon AP, Wu PC, Gray F, Atkins M, Stevenson C, Barber J, Brown N, Crowther L, Woessner M. 1999. Lamivudine treatment reduces progression to cirrhosis in patients with chronic hepatitis B. J Hepatol 30(Suppl):59 (Abstract GS5/26).
17. Hadziyannis S, Bramou T, Makris A, Moussoulis G, Zignego L, Papaioannou C. 1990. Interferon alfa-2b treatment of HBeAg negative/ serum HBV DNA positive chronic active hepatitis type B. J Hepatol 11:8133-8136.
18. Hassanein T, Colantoni A, De Maria N, van Thiel DH. 1996. Interferon-α 2b improves short-term survival in patients transplanted for chronic liver failure caused by hepatitis B. J Viral Hepat 3: 333-340.
19. Hoofnagle JH, Di Bisceglie AM. 1997. The treatment of chronic viral hepatitis. N Engl J Med 336:347-356.
20. Johnson MA, Moore KHP, Yuen GJ, Bye A, Pakes GE. 1999. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinetic 36:41-66.
21. Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. 1991. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 114:629-634.
22. Lai CL, Ching CK, Tung AK, Young J, Hill A, Wong BC, Dent J, Wu PC. 1997. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 25:241-244.
23. Lai C-L, Chien R-N, Leung NWY, Chang T-T, Guan R, Tai D-I, Ng K-Y, Wu P-C, Dent JC, Barber J, Stephenson SL, Gray DF, for the Asia Hepatitis Lamivudine Study Group. 1998. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339:61-68.
24. Leung N, Dienstag J, Schiff E, Sullivan M, Atkins M, Grice R, Woessner M, Brown N, Hunt CM. 1998. Clinical safety profile of lamivudine treatment in a large cohort of hepatitis B patients. Hepatology 28:587A (Abstract 1698).
25. Leung N. 2000. Liver disease - significant improvement with lamivudine. J Med Virol 61:380-385.
26. Liu SM, Sheen IS, Chien RN, Chu CM, Liaw YF. 1999. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 29:971-975.
27. Marinos G, Smith HM, Naoumov NV, Williams R. 1994. Quantitative assessment of serum IgM anti-HBc in the natural course and during interferon treatment of chronic hepatitis B virus infection. Hepatology 19:303-311.
28. Mutimer D, Naoumov N, Honkoop P, Marinos G, Ahmed M, de Man R, McPhillips P, Johnson M, Williams R, Elias E, Schalm S. 1998. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. J Hepatol 28:923-929.
29. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, Fevery J, De Man RA, Thomas HC. 1997. Lamivudine therapy for chronic hepatitis B: six-month randomised dose-ranging study. Gastroenterology 113:1258-1263.
30. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Häussinger D. 1996. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334:1422-1427.
31. Pastore G, Santantonio T, Milella M, Monno L, Mariano N, Moschetta R, Pollice L. 1992. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum; response to a 6-month course of lymphoblastoid interferon. J Hepatol 14:221-225.
32. Perrillo RP. 1993. Interferon in the management of chronic hepatitis B. Dig Dis Sci 38:577-593.
33. Perrillo RP. 1994. The management of chronic hepatitis B. Am J Med 96(Suppl 1A):34S-40S.
34. Perrillo RP, Schalm SW, Schiff ER, Brown NA, Woessner MA, Sullivan M. 1999. Predictors of HBeAg seroconversion in chronic hepatitis B patients treated with lamivudine. Hepatology (Abstract).
35. Rizzetto M. 2000. The response of pre-core mutant chronic hepatitis B infection to lamivudine. J Med Virol 61:398-402.
36. Schalm SW, Heathcote J, Cianciara J, Farrell G, Shermann M, Willems B, Dhillon A, Moorat A, Barber J, Gray DF on behalf of an International Lamivudine Study Group. 2000. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 46:562-568.
37. Schiff E, Karayalcin S, Grimm I, Perrillo R, Dienstag J, Husa P, Schalm S, Crowther L, Sullivan M, Woessner M, McPhillips P, Brown N, and the International Lamivudine Investigator Group. 1998a. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology 28:388A (Abstract 901).
38. Schiff E, Cianciara J, Kowdley K, Norkrans G, Perrillo R, Tong M, Crowther L, Wakeford J, Woessner M, Stevenson C, Brown N, and the International Lamivudine Investigator Group. 1998b. Durability of HBeAg seroconversion after lamivudine monotherapy in controlled phase II and III trials. Hepatology 28:163A (Abstract 1).
39. Schift E. 2000. Lamivudine for hepatitis B in clinical practice. J Med Virol 2000, 61:386-391.
40. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF, and the Lamivudine Precore Mutant Study Group. 1999. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 29:889-896.
41. Tyrrell DLJ, Mitchell MC, De Man RA et al. 1993. Phase II trial of lamivudine for chronic hepatitis B. Hepatology 18:112A.
42. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. 1993. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Int Med 119:312-323.
43. Yao G, Wang B, Cui Z, Yao J, Minde Z. 1999. Long-term efficacy of lamivudine in the treatment of patients with chronic hepatitis B virus infection - a multicenter, randomised, double-blind, placebo controlled trial. Gastroenterology 116:A848 (Abstract G3688).